On another note to this stock,
Saxien, a HC poster wrote to the management about a US "inhaled" treatment for diabetes that I came across in the papers, which would have cut across Eiffel's planned intro with their diabetes product based on the supercriticaql fluid treatment.
To date Saxien hasn't had a reply from Eiffel and in itself thats very disappointing.
However, the technology holds lotsa prospect.
I guess we'll wait for Saxien to get a reply.
EIF
eiffel technologies limited
